April 12, 2021

Real-World Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Pre-print, not peer-reviewed] Monoclonal antibody treatment significantly reduced the risk of subsequent emergency department visit or hospitalization among patients with COVID-19 (n = 598) in a real-world study using electronic health record data. Among 270 (45%) patients treated with the monoclonal antibody bamlanivimab, 5 (1.9%) presented to the emergency department (ED) or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared to 39 of 328 (12%) untreated patients. The risk of an ED visit or hospitalization was 82% lower in patients treated with bamlanivimab than untreated patients after adjusting for age, gender, and comorbidities.

Rainwater-Lovett et al. (Apr 10, 2021). Real-World Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States. Pre-print downloaded Apr 12 from https://doi.org/10.1101/2021.04.08.21254705